Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02062385
Other study ID # V260-024
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date May 30, 2014
Est. completion date June 11, 2015

Study information

Verified date October 2018
Source Merck Sharp & Dohme Corp.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will assess the efficacy, safety, and immunogenicity of a 3-dose regimen of RotaTeq™ (V260) in healthy Chinese infants. Approximately 4040 participants at least 6 weeks and up to 12 weeks of age at the time of the first vaccination with V260 or placebo will be enrolled and randomized (1:1) to receive either V260 or placebo. Participants will also receive the routine China Expanded Program on Immunization (EPI) vaccines (oral poliovirus vaccine [OPV] and diphtheria, tetanus, and acellular pertussis vaccine [DTaP]) either staggered or concomitantly with V260 or placebo. All participants will be followed for efficacy and safety. Immune responses to OPV and DTaP will be evaluated in a subset of participants. The primary hypothesis of the study states that V260 will be efficacious in preventing any severity of rotavirus gastroenteritis as compared with placebo.


Recruitment information / eligibility

Status Completed
Enrollment 4040
Est. completion date June 11, 2015
Est. primary completion date June 11, 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 6 Weeks to 12 Weeks
Eligibility Inclusion Criteria:

- Healthy infants at least 6 weeks (42 days) and up to 12 weeks (84 days) of age at the time of the first study vaccination

- Parent/legal guardian agrees to participate by giving written informed consent and is willing and able to comply with study requirements

Exclusion Criteria:

- History of congenital abdominal disorders, prior rotavirus gastroenteritis, chronic diarrhea, failure to thrive, or abdominal surgery

- History of intussusception

- Impairment of immunological function, including Severe Combined Immunodeficiency (SCID)

- Acute disease, severe chronic disease, or chronic disease during the acute period

- Uncontrolled epilepsy, encephalopathy, seizure, or other progressive neurological disease

- Hypersensitivity to any component of the rotavirus vaccine, OPV, or DTaP

- Prior receipt of any rotavirus vaccine

- Fever, with an axillary temperature >=37.5 °C (or equivalent) within 24 hours before study vaccination (study vaccination can be deferred until complete resolution of febrile illness)

- Clinical evidence of active gastrointestinal illness

- Received intramuscular, oral, or intravenous corticosteroid treatment since birth (topical, ophthalmic, and inhaled steroids are permitted)

- Resides in a household with an immunocompromised person

- Receipt of a blood transfusion or blood products, including immunoglobulins

- Participation in another interventional study within 14 days before the first study vaccination or during the study

- Receipt of an investigational or non-registered product other than the study vaccine within 30 days before the first study vaccination or during the study

- For participants in immunogenicity arms: inability to obtain a blood specimen at randomization visit (note: the visit may be rescheduled so that a baseline specimen may be obtained); history of polio, diphtheria, tetanus, or pertussis disease; previous vaccination against diphtheria, tetanus, pertussis, or poliomyelitis

- Any condition which, in the opinion of the investigator, may interfere with the evaluation of the study objectives

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
V260
V260 (RotaTeq™; live, oral, pentavalent rotavirus vaccine)
Placebo to V260
Placebo control
OPV
Oral poliovirus vaccine administered according to the standard of care
DTaP
Diphtheria, Tetanus, Acellular Pertussis vaccine administered according to the standard of care

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Merck Sharp & Dohme Corp.

References & Publications (1)

Mo Z, Mo Y, Li M, Tao J, Yang X, Kong J, Wei D, Fu B, Liao X, Chu J, Qiu Y, Hille DA, Nelson M, Kaplan SS. Efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RV5) in healthy Chinese infants: A randomized, double-blind, p — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Any Severity of Rotavirus Gastroenteritis The number of participants with rotavirus gastroenteritis (RVGE) caused by naturally-occurring wild-type rotavirus (regardless of serotype or disease severity) was assessed. The case definition of RVGE included 1) 3 or more watery or looser-than-normal stools within a 24-hour period and/or forceful vomiting, and 2) naturally-occurring wild-type rotavirus must be detected in a stool specimen taken within 7 days after the onset of symptoms. From 14 days after the third dose of V260 or placebo through the first rotavirus season (up to 15 months)
Secondary Percentage of Participants With Elevated Temperature Elevated temperature (temperature >=37.5°C axillary or equivalent) was noted by the guardian and recorded on the Vaccination Report Card during Day 1 to Day 14 after each dose of vaccination. Elevated temperature reported by the guardian was also collected as an adverse event (pyrexia) during Day 15 to Day 30 after each dose of vaccination. The percentage of participants with axillary temperature >=37.5 °C or an adverse event of pyrexia was assessed. Up to 30 days after any dose of V260 or Placebo
Secondary Percentage of Participants With Vomiting or Diarrhea Episodes of vomiting and diarrhea were noted by the guardian and recorded on the Vaccination Record Card during Day 1 to Day 14 after each dose of vaccination. Vomiting and diarrhea reported by the guardian were also collected as an adverse event during Day 15 to Day 30 after any dose of vaccination. The percentage of participants with an episode or an adverse event of vomiting or diarrhea was assessed. Up to 30 days after any dose of V260 or Placebo
Secondary Percentage of Participants With Intussusception Episodes of intussusception were collected from the time of written consent until the end of study. The percentage of participants with an episode of intussusception was assessed. Up to 15 months
Secondary Number of Participants With Severe Rotavirus Gastroenteritis The number of participants with severe rotavirus gastroenteritis (RVGE) caused by naturally-occurring wild-type rotavirus (regardless of serotype or disease severity) was assessed. The case definition of RVGE included 1) 3 or more watery or looser-than-normal stools within a 24-hour period and/or forceful vomiting, and 2) naturally-occurring wild-type rotavirus must be detected in a stool specimen taken within 7 days after the onset of symptoms. Severe RVGE was defined as >=11 on the Vesikari Scoring System, a composite of the seven parameters related to symptoms and treatment with an overall range from 0 to 20. From 14 days after the third dose of V260 or placebo through the first rotavirus season (up to 15 months)
Secondary Percentage of Participants Who Achieved Seroprotection Against Poliovirus Type 1, 2, or 3 The percentage of participants who achieved seroprotection against poliovirus Type 1, 2, or 3 was assessed. Seroprotection was defined as a neutralizing antibody titer >=1:8. This outcome was evaluated only in participants receiving concomitant administration of V260 and OPV. Baseline and between 28 and 56 days after the third OPV vaccination
Secondary Percentage of Participants With Any Adverse Event An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the sponsor's product, is also an adverse event. Up to 30 days after any dose of V260 or Placebo
Secondary Percentage of Participants Seropositive to Diphtheria, Pertussis, or Tetanus Antigens The percentage of participants seropositive to diphtheria, pertussis, or tetanus antigens was assessed. Seropositive was defined as the following: 1) anti-diphtheria antibody titers >=0.1 International Units (IU)/mL, 2) anti-tetanus antibody titers >=0.1 IU/mL, 3) antipertussis toxin antibody titers >=20 Enzyme-linked Immunosorbent Assay (ELISA) Units (EU)/mL, 4) anti-pertussis filamentous hemagglutinin (FHA) antibody titers >=20 EU/mL. This outcome was evaluated only in participants receiving concomitant administration of V260 and EPI. Baseline and between 28 and 51 days after the third DTaP vaccination
See also
  Status Clinical Trial Phase
Completed NCT01575197 - Evaluation of the Human Rotavirus Vaccine at Varying Schedules and Doses in Rural Ghana Phase 4
Completed NCT01202201 - A Retrospective Survey of the Burden of Rotavirus Gastroenteritis (RV GE) and Nosocomial RV GE in Japan N/A
Completed NCT00953056 - A Study of V260 in Healthy Chinese Adults, Children and Infants (V260-028)(COMPLETED) Phase 1
Completed NCT00737503 - Introduction of an Oral Live Human Rotavirus (Rotarix) Vaccine in Matlab Phase 4
Completed NCT04185545 - Efficacy, Safety and Immunogenicity of Rotavirus RV3 Vaccine (Bio Farma) in Neonates Phase 3
Completed NCT03474055 - Study on Liquid Bovine Rotavirus Pentavalent Vaccine (LBRV-PV) to Evaluate Lot-to-Lot Consistency and to Compare Non-Inferiority With ROTASIIL (Lyophilized BRV-PV) in Healthy Infants in India Phase 2/Phase 3
Completed NCT01236066 - Impact of Rotavirus Vaccination on Hospitalisations for Rotavirus Gastroenteritis in Children Aged <5 Years in Australia N/A
Completed NCT00489567 - Hospital-based Surveillance to Collect Prospective Data to Estimate the Disease Burden of Severe RV GE in Sweden N/A
Completed NCT02584816 - Phase III Study on Rotavirus Vaccine to Evaluate Lot-to-lot Consistency and Interference With Routine UIP Immunization Phase 3
Completed NCT02133690 - A Clinical Trial to Study the Effect and Safety of Rotavirus Vaccine Against Severe Rotavirus Gastroenteritis in Healthy Indian Infants Phase 3
Completed NCT01177657 - Study to Evaluate the Effectiveness of Rotarix™ Against Severe Gastroenteritis Among Hospitalized Children in Brazil N/A
Completed NCT00740935 - Impact of Systematic Infants Vaccination Against Rotavirus on Gastroenteritis Hospitalization: a Prospective Study in Brest District, France. Phase 4
Completed NCT01265355 - Community Based Prevention of Rotavirus Gastroenteritis by a Functional Food Supplement Phase 2/Phase 3
Completed NCT00169455 - Assess the Immunogenicity of the Human Rotavirus (HRV) Vaccine After Reconstitution Without Buffering Agent; & Evaluate the Immunogenicity, Reactogenicity & Safety of the Vaccine After Storage for 7 d at 37°C Following 2 Doses in Healthy Infants Phase 3
Completed NCT04819412 - To Determine the Safety and Efficacy of Liquid ROTAVAC 5C Vaccine Against Childhood Diarrhea Caused by Rotavirus Phase 3
Completed NCT02728869 - Safety, Reactogenicity and Immunogenicity of Heat-stable Rotavirus Vaccine (HSRV) in Adults and Infants Phase 1/Phase 2
Recruiting NCT05958771 - The Efficacy of Three Doses of Live Attenuated, Oral Rotavirus Vaccine 116E Phase 3
Recruiting NCT01061658 - Safety and Immunogenicity Study of the Tetravalent Rotavirus Vaccine Phase 1/Phase 2
Completed NCT01508533 - Epidemiology of Rotavirus Infection in North India Community N/A
Completed NCT01026779 - Rotavirus Gastroenteritis and Vaccine Usage in Rhode Island